HIV Treatment Bulletin - Vol. 6, No. 6, June 2005
Polly Clayden, HIV i-Base

In an oral presentation David Hawkins summarised the updated BHIVA pregnancy guidelines, which have “been some while in their gestation”. They are due to be published in July 2005 issue of HIV Medicine and are currently on the BHIVA website. [1, 2]

In an oral presentation, Esse Menson presented findings from the Collaborative HIV Paediatric Study (CHIPS), evaluating the extent to which HIV positive children have been under-dosed with antiretrovirals between 1997 and March 2005.

The CHIPS cohort includes 934 children from 23 centres in the UK and Ireland. 80% of all known HIV positive children are under follow up in this study, 73% of whom had received antiretroviral drugs. The children evaluated were aged between two and 12 years.

The authors defined underdosing as having received <90% of the current recommended minimum doses (CRD) in the Paediatric European Network for the Treatment of AIDS (PENTA) guidelines.

Children were underdosed for 42% of the time. Very high rates of underdosing of nelfinavir were reported when the drug was first available: 62% in the time period 1997 to 1999, falling to 21% in the period 2003 to 2005; nevirapine was under-dosed in 38% children in 1997 to 1999 and 16% in 2003 to 2005, and efavirenz was under-dosed in 17% of children in 2003-2005. Underdosing was also seen with the nucleoside analogues varied between 7% (with ddI) and 21% (with d4T).

Prevalence of under dosing was reduced over time - particularly with nevirapine and nelfinavir, as more data became available, and guidelines were updated. Underdosing was less frequent with lopinavir/ritonavir, 4% in the period 2003 to 2005 (the drug was not used in the earlier time periods).

Dr Menson also described potential confusions with inconsistencies of recommended dosing calculation strategy ie weight, body surface area or age bands. Efavirenz, when dosed according to weight band resulted in underdosing when the child reached the end of each weight band.

In a small sub-study, a case note review of 53 children’s records from one centre was performed. The authors reported that “failure to increase dose as child grew and rounding down of doses”, were given as the reasons for under dosing in 56% of the cases and “formulation limitations” and “clinical indication/drug interaction” in 33% and 5% cases respectively.

This clinic cited “system failures” in the early years of prescribing ART to children, eg children missing appointments, lack of pharmacy checks, and the time lag between prescription and administration of new dose as potential causes. These issues have since been addressed, perhaps contributing to the reduction in underdosing observed over time.

The authors concluded: “Largely unwittingly we have greatly under-dosed HIV-infected children on ART over the past seven years.”

Comments

Dr Menson suggested that these results may be the ‘tip of the iceberg’ and there was much discussion after the talk that they could make a strong argument for therapeutic drug monitoring (TDM) in children.

For clinics that do not already use TDM routinely, PENTA 14, a randomised trial of differing levels of TDM compared with no TDM in children starting or switching to a new antiretroviral regimen is currently recruiting in the UK. Please visit the trials section of the PENTA website for more details.

PENTA Trials.
http://www.ctu.mrc.ac.uk/penta/trials.htm

Ref: Menson EN, Walker AS, Duong et al. Extent of under dosing of antiretroviral therapy in HIV-infected children. BHIVA Conf 2005 Apr 20-23;11: Abstract No.O36.

050610
IB050606-04

©2005. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone / Firestone Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.